Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers

NCT02515877 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer

Interventions

RADIATION: External radiotherapy + curietherapy
DRUG: Vistide
DRUG: Carboplatin

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

[object Object]